Esperion Therapeutics (ESPR) Status Update summary

Strategic Vision and Financial Outlook

• Focus on global expansion of the bempedoic acid franchise, aiming for blockbuster sales over $1 billion, with launches in the US, Europe, and Japan through partnerships.

• Three-pillar strategy includes sustainable profitability, pipeline advancement, and revenue growth driven by increased prescription demand and global partnerships.

• FY 2025 R&D guidance is $55–65M; SG&A: $160–170M; total OpEx: $215–235M, including ~$15M non-cash stock-based compensation.

• Strengthened balance sheet supports portfolio expansion and pipeline advancement.

• Ongoing evolution into a leading global biopharmaceutical company through commercial execution, partnerships, and pipeline advancement.

Next-Generation ACLY Inhibitor Program and Scientific Rationale

• Next-generation ACLY inhibitors, including lead candidate ESP-1336, are designed to target multiple liver cell types and address injury, inflammation, and fibrosis in PSC and other liver diseases.

• Multi-omic, genetic, and phenome-wide association studies validate ACLY as a therapeutic target, showing causal links to liver disorders such as MASLD and PSC.

• Preclinical models demonstrate ESP-1336 reduces fibrosis, inflammation, and liver injury across several PSC-relevant disease models, with efficacy in human liver microtissues and animal models.

• Rational drug design and advanced bioinformatics have enabled the discovery of highly potent, specific allosteric ACLY inhibitors optimized for once-daily oral dosing.

• ACLY inhibition modulates acetyl-CoA levels in hepatobiliary cells, potentially disrupting key PSC disease pathways.

Disease Focus: Primary Sclerosing Cholangitis (PSC)

• PSC is a rare, progressive, immune-mediated liver disease with no approved therapies, leading to significant morbidity, need for transplants, and high patient burden.

• Estimated over 76,000 diagnosed PSC patients in the US and Europe as of 2024, representing a market opportunity exceeding $1 billion annually.

• ESP-1336 targets all three mechanisms of PSC progression: cholestasis/injury, inflammation, and fibrosis.

• Lead program may be eligible for Orphan Drug and Fast Track designations from the FDA.

• Early clinical trials will likely focus on established but not end-stage PSC, using non-invasive biomarkers and imaging to assess efficacy.